New Horizontal Merger Guidelines Indicate Greater Scrutiny of High Tech and Pharmaceutical Transactions
It also indicates greater Agency scrutiny of such transactions in industries characterized by differentiated products and high levels of R&D spendingÃ¢â‚¬â€such as the high tech and pharmaceutical industries. Janet McDavid & Eric Stock (Hogan Lovells)
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
When requesting a correction, please mention this item's handle: RePEc:cpi:atchrn:10.2.2010:i=5719. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Lindsay McSweeney)
If references are entirely missing, you can add them using this form.